Journal Article

DKFZ-2020-01118

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png A genetic risk score to personalize prostate cancer screening, applied to population data.

Huynh-Le, M.-P. ; Fan, C. C. ; Karunamuni, R. ; Walsh, E. I. ; Turner, E. L. ; Lane, J. A. ; Martin, R. M. ; Neal, D. E. ; Donovan, J. L. ; Hamdy, F. C. ; Parsons, J. K. K. ; Eeles, R. A. ; Easton, D. F. ; Kote-Jarai, Z. ; Amin Al Olama, A. ; Benlloch Garcia, S. ; Muir, K. ; Grönberg, H. ; Wiklund, F. ; Aly, M. ; Schleutker, J. ; Sipeky, C. ; Tammela, T. ; Nordestgaard, B. G. ; Key, T. J. ; Travis, R. C. ; Pharoah, P. D. P. ; Pashayan, N. ; Khaw, K.-T. ; Thibodeau, S. N. ; McDonnell, S. K. ; Schaid, D. J. ; Maier, C. ; Vogel, W. ; Luedeke, M. ; Herkommer, K. ; Kibel, A. S. ; Cybulski, C. ; Wokolorczyk, D. ; Kluzniak, W. ; Cannon-Albright, L. A. ; Brenner, H.DKFZ* ; Schöttker, B.DKFZ* ; Holleczek, B. ; Park, J. Y. ; Sellers, T. A. ; Lin, H.-Y. ; Slavov, C. K. ; Kaneva, R. P. ; Mitev, V. I. ; Batra, J. ; Clements, J. A. ; Spurdle, A. B. ; Teixeira, M. R. ; Paulo, P. ; Maia, S. ; Pandha, H. ; Michael, A. ; Mills, I. G. ; Andreassen, O. A. ; Dale, A. M. ; Seibert, T. M.

2020
AACR Philadelphia, Pa.

This record in other databases:  

Please use a persistent id in citations: doi:10.1158/1055-9965.EPI-19-1527

Abstract: A polygenic hazard score (PHS)-the weighted sum of 54 SNP genotypes-was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we assess the potential impact of PHS-informed screening.UK population incidence data (Cancer Research UK) and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer were combined to estimate age-specific clinically significant prostate cancer incidence (Gleason≥7, stage T3-T4, PSA ≥10, or nodal/distant metastases). Using hazard ratios estimated from the ProtecT prostate cancer trial, age-specific incidence rates were calculated for various PHS risk percentiles. Risk-equivalent age-when someone with a given PHS percentile has prostate cancer risk equivalent to an average 50-year-old man (50-years-standard risk)-was derived from PHS and incidence data. Positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was calculated using PHS-adjusted age groups.The expected age at diagnosis of clinically significant prostate cancer differs by 19 years between the 1st and 99th PHS percentiles: men with PHS in the 1st and 99th percentiles reach the 50-years-standard risk level at ages 60 and 41, respectively. PPV of PSA was higher for men with higher PHS-adjusted age.PHS provides individualized estimates of risk-equivalent age for clinically significant prostate cancer. Screening initiation could be adjusted by a man's PHS.Personalized genetic risk assessments could inform prostate cancer screening decisions.

Note: 2020 Sep;29(9):1731-1738

---

Contributing Institute(s):

1. C070 Klinische Epidemiologie und Alternf. (C070)
2. Präventive Onkologie (C120)
3. DKTK HD zentral (HD01)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2020

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Essential Science Indicators ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---